<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Measles, mumps, and rubella immunization in infants, children, and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Measles, mumps, and rubella immunization in infants, children, and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Measles, mumps, and rubella immunization in infants, children, and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jan E Drutz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julie A Boom, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Teresa K Duryea, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1276243470">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Childhood and adolescent immunizations are one of the most effective means of preventing serious illness. Combination measles, mumps, and rubella (MMR) immunization in infants, children, and adolescents will be discussed here. MMR immunization in adults is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3893.html" rel="external">
          "Measles, mumps, and rubella immunization in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1276241566">
         <span class="h1">
          MEASLES, MUMPS, AND RUBELLA DISEASE
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Measles
         </strong>
         – The measles virus causes an acute infection characterized by fever, cough, coryza, conjunctivitis, rash  (
         <a class="graphic graphic_picture graphicRef57093 graphicRef57803" href="/z/d/graphic/57093.html" rel="external">
          picture 1A-B
         </a>
         ), and enanthem  (
         <a class="graphic graphic_picture graphicRef57571 graphicRef131901" href="/z/d/graphic/57571.html" rel="external">
          picture 2A-B
         </a>
         ) that may be followed by severe complications, including encephalitis. (See
         <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">
          "Measles: Clinical manifestations, diagnosis, treatment, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mumps
         </strong>
         – The mumps virus causes an acute viral syndrome with parotid swelling  (
         <a class="graphic graphic_picture graphicRef53503" href="/z/d/graphic/53503.html" rel="external">
          picture 3
         </a>
         ). Mumps infection usually is self-limited but may be associated with complications, including orchitis and oophoritis, aseptic meningitis, and encephalitis. (See
         <a class="medical medical_review" href="/z/d/html/8310.html" rel="external">
          "Mumps", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rubella
         </strong>
         – The rubella virus causes German measles, a generally mild infection with a characteristic rash  (
         <a class="graphic graphic_picture graphicRef61263" href="/z/d/graphic/61263.html" rel="external">
          picture 4
         </a>
         ) that can affect both children and adults. However, rubella infection early in pregnancy can cause congenital anomalies (eg, hearing loss; cataracts  (
         <a class="graphic graphic_picture graphicRef64979" href="/z/d/graphic/64979.html" rel="external">
          picture 5
         </a>
         ); cardiac disease; and neurodevelopmental effects, including intellectual disability and autism spectrum disorder [ASD]). (See
         <a class="medical medical_review" href="/z/d/html/8301.html" rel="external">
          "Rubella", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8312.html" rel="external">
          "Rubella in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6047.html" rel="external">
          "Congenital rubella", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2831945672">
         <span class="h1">
          VACCINE EFFECTIVENESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine immunization with measles, mumps, and rubella-containing vaccine is effective in preventing measles, mumps, and rubella infections, as indicated by the decline in the number of cases of measles, mumps, and rubella in the United States following the introduction of these vaccines in the 1960s  (
         <a class="graphic graphic_figure graphicRef101586 graphicRef101590 graphicRef70446" href="/z/d/graphic/101586.html" rel="external">
          figure 1A-C
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Measles
         </strong>
         – In a meta-analysis of cohort studies, the effectiveness of one dose of measles-containing vaccine in children was 95 percent (95% CI 87-98 percent) after one dose and 96 percent (95% CI 71-99 percent) after two doses [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Global measles vaccination is estimated to have prevented more than 25 million deaths during 2000 to 2019 [
         <a href="#rid3">
          3,4
         </a>
         ]. Measles incidence decreased from 145 to 18 cases per one million population between 2000 and 2016; however, in 2019, measles incidence increased fivefold compared with 2016. Unfortunately, millions of children failed to receive measles vaccines during the coronavirus disease 2019 (COVID-19) pandemic. As a result, measles cases increased 18 percent and measles deaths increased 43 percent in 2022.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Measles outbreaks predominantly occur in unvaccinated individuals [
         <a href="#rid5">
          5-7
         </a>
         ]. When measles occurs in individuals who received ≥2 doses of measles-containing vaccine, it is less severe than in those who received only one dose or who are unvaccinated [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3019.html" rel="external">
          "Measles: Epidemiology and transmission", section on 'Measles control'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Measles immunization programs have also been associated with decreased childhood morbidity and mortality from nonmeasles infectious diseases [
         <a href="#rid8">
          8-11
         </a>
         ], perhaps by preventing the loss of immune memory cells that occurs with natural measles infection [
         <a href="#rid12">
          12-16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">
          "Measles: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Immune suppression and secondary infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mumps
         </strong>
         – In a meta-analysis of cohort studies, the effectiveness of Jeryl-Lynn strain mumps-containing vaccine in children was 72 percent (95% CI 38-87 percent) after one dose and 86 percent (95% CI 73-93 percent) after two doses [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Despite the effectiveness of mumps immunization, mumps outbreaks occur. Outbreaks of mumps in vaccinated populations raise concern about waning immunity [
         <a href="#rid17">
          17,18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8310.html" rel="external">
          "Mumps", section on 'Outbreaks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rubella
         </strong>
         – In systematic review, the effectiveness of rubella vaccine in children was 89 percent (95% CI 58-97 percent) in a single cohort study [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Endemic rubella and congenital rubella syndrome were eliminated from the United States in 2005 and from the rest of the Americas in 2015 [
         <a href="#rid19">
          19,20
         </a>
         ]. However, sporadic cases of rubella continue to be reported in the United States, particularly among immigrant populations [
         <a href="#rid21">
          21,22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8301.html" rel="external">
          "Rubella", section on 'Outbreaks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1276241676">
         <span class="h1">
          VACCINE FORMULATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monovalent vaccines
         </strong>
         –
         <strong>
         </strong>
         Single antigen (ie, monovalent) formulations of measles, mumps, and rubella vaccines are available for use in countries that have not yet implemented routine immunization against rubella and/or mumps. In countries that have implemented routine infant immunization against measles, mumps, and rubella, the World Health Organization recommends the combination measles, mumps, and rubella vaccine [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combination vaccines
         </strong>
         – Two types of combination measles, mumps, and rubella-containing vaccines are available for use in countries that routinely immunize against measles, mumps, and rubella [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MMR –
         <a class="drug drug_pediatric" data-topicid="12943" href="/z/d/drug information/12943.html" rel="external">
          Measles-mumps-rubella vaccine
         </a>
         (MMR) is a live attenuated vaccine that includes measles, mumps, and rubella [
         <a href="#rid1">
          1,24
         </a>
         ]. In the United States, MMR is licensed for routine use in individuals ≥12 months of age. Two formulations are available in the United States:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         M-M-R II contains Edmonston-Enders measles strain, Jeryl-Lynn mumps strain, and Wistar RA 27/3 rubella strain.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Priorix contains Schwartz measles strain, Jeryl-Lynn derived mumps strain, and Wistar RA 27/3 rubella strain.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         M-M-R II and Priorix can be used interchangeably [
         <a href="#rid24">
          24
         </a>
         ]. Both formulations contain small amounts of
         <a class="drug drug_pediatric" data-topicid="12634" href="/z/d/drug information/12634.html" rel="external">
          neomycin
         </a>
         . M-M-R II contains gelatin, but Priorix does not [
         <a href="#rid1">
          1,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MMRV –
         <a class="drug drug_pediatric" data-topicid="12990" href="/z/d/drug information/12990.html" rel="external">
          Measles-mumps-rubella-varicella virus vaccine
         </a>
         (MMRV) is a live attenuated vaccine that includes measles (Edmonston-Enders strain), mumps (Jeryl-Lynn vaccine strain), rubella (Wistar RA 27/3 vaccine strain), and varicella (Oka strain). In the United States, it is licensed for use in children 12 months through 12 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         MMRV contains small amounts of
         <a class="drug drug_pediatric" data-topicid="12634" href="/z/d/drug information/12634.html" rel="external">
          neomycin
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1276243721">
         <span class="h1">
          INDICATIONS AND SCHEDULES
         </span>
        </p>
        <p class="headingAnchor" id="H1787929993">
         <span class="h2">
          United States
         </span>
        </p>
        <p class="headingAnchor" id="H1787930105">
         <span class="h3">
          Routine immunization
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, routine immunization with
         <a class="drug drug_pediatric" data-topicid="12943" href="/z/d/drug information/12943.html" rel="external">
          measles-mumps-rubella vaccine
         </a>
         (MMR) or
         <a class="drug drug_pediatric" data-topicid="12990" href="/z/d/drug information/12990.html" rel="external">
          measles-mumps-rubella-varicella virus vaccine
         </a>
         (MMRV) consists of two doses: the first at age 12 through 15 months and the second at age 4 through 6 years [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First dose
         </strong>
         – The first dose is usually given at age 12 to 15 months following the decline of passively acquired maternal measles antibody, which interferes with the immune response [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective randomized trial, antimeasles antibody developed in 87 percent of children vaccinated at 9 months, 95 percent of those vaccinated at 12 months, and 98 percent of those vaccinated at 15 months of age [
         <a href="#rid25">
          25
         </a>
         ]. In several studies, the median seroconversion rates for measles, mumps, and rubella after one dose of MMR were ≥94 percent; immunity appears to be long lasting  (
         <a class="graphic graphic_table graphicRef101589" href="/z/d/graphic/101589.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid27">
          27-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although systematic reviews of clinical studies and a subsequent observational study indicate that administration of the first dose of measles-containing vaccine to infants before nine months of age is safe and immunogenic, it is associated with lower antibody titers, antibody functionality, and effectiveness than administration at ≥9 months of age [
         <a href="#rid37">
          37-39
         </a>
         ]. Thus, in the United States and other countries where endemic measles has been eliminated and measles vaccine coverage is high, early administration of the first dose is indicated only for high-risk infants (eg, in an outbreak, measles exposure, or international travel). (See
         <a class="local">
          'International travel and outbreaks'
         </a>
         below and
         <a class="local">
          'Measles postexposure prophylaxis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Delay of the first dose beyond age 12 to 15 months increases the duration of susceptibility and has contributed to large measles outbreaks in the United States [
         <a href="#rid40">
          40-43
         </a>
         ]. Delay of the first dose of MMR beyond 15 months of age has also been associated with an increased risk of seizures in the 7 to 10 days after immunization [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="local">
          'Adverse effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second dose
         </strong>
         – Although the second dose is usually recommended at age 4 to 6 years, it can be given sooner. The timing depends on the formulation [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MMR can be given ≥28 days after the first dose, provided that both doses are given at ≥12 months of age
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MMRV can be given ≥3 months after the previous dose of varicella-containing vaccine, provided that both doses are given at ≥12 months of age
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         When reviewing immunization records, MMRV doses that were given ≥28 days after the first dose of varicella-containing vaccine need not be repeated [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The second dose of measles, mumps, and rubella-containing vaccine may elicit an antibody response in children who do not respond to the first dose. Nearly all children who do not respond to the first dose respond to the second [
         <a href="#rid47">
          47,48
         </a>
         ]. The second dose is routinely administered before school entry (four to six years) because the risk of measles is greater in school-age than in preschool children and the risk of adverse events is lower at four to six years than in older children [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential indications for a third dose
         </strong>
         – A third dose of MMR is not routinely recommended but may be indicated:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         During a mumps outbreak (see
         <a class="local">
          'International travel and outbreaks'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If the first dose of MMR was given before age 12 months (eg, for international travel, during an outbreak, or for postexposure prophylaxis); doses administered before age 12 months are considered invalid and should be repeated at ≥12 months of age (see
         <a class="local">
          'International travel and outbreaks'
         </a>
         below and
         <a class="local">
          'Measles postexposure prophylaxis'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1383908509">
         <span class="h3">
          Catch-up immunization
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence of immunity
         </strong>
         – In children and adolescents in the United States, evidence of immunity is established by any of the following  (
         <a class="graphic graphic_table graphicRef134368" href="/z/d/graphic/134368.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Documentation of age-appropriate vaccination with a live attenuated vaccine:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For measles – Two doses of measles-containing vaccine, both administered at ≥12 months of age, separated by ≥28 days (doses administered before 12 months of age are not counted).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For mumps – Two doses of mumps-containing vaccine, both administered at ≥12 months of age, separated by ≥28 days (doses administered before 12 months of age are not counted).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For rubella – One dose of rubella-containing vaccine administered at ≥12 months of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Evidence of rubella immunity in pregnant people is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy", section on 'Preconception immunization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Parent- or caregiver-reported doses are
         <strong>
          not
         </strong>
         valid without appropriate documentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If serologic testing is performed, serologic evidence of immunity (ie, positive serum measles, mumps, and rubella immunoglobulin [Ig] G).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laboratory confirmation of measles, mumps, or rubella disease (ie, detection of measles viral ribonucleic acid [RNA] by reverse transcriptase polymerase chain reaction, detection of measles virus-specific IgM, or a fourfold increase in measles IgG in acute and convalescent specimens) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical diagnosis without laboratory confirmation is insufficient evidence of immunity. (See
         <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">
          "Measles: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8310.html" rel="external">
          "Mumps", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8301.html" rel="external">
          "Rubella", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for catch-up or revaccination
         </strong>
         – Catch-up immunization is indicated for children who lack appropriate evidence of immunity to measles, mumps, or rubella  (
         <a class="graphic graphic_table graphicRef134368" href="/z/d/graphic/134368.html" rel="external">
          table 2
         </a>
         ) or whose immunization status is unknown [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Serologic testing is not necessary before catch-up vaccination. However, if it is performed in postpubertal females, those who have negative rubella serology despite age-appropriate vaccination should receive an additional dose of MMR vaccine (maximum of three doses). Serologic testing is not necessary after the third dose. In observational studies, administration of a third dose of MMR has not been associated with increased rates of adverse effects [
         <a href="#rid51">
          51-54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other individuals with age-appropriate measles, mumps, and rubella immunization who lack serologic evidence of immunity do not need catch-up vaccination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Catch-up schedule
         </strong>
         – The catch-up regimen varies with age, the number of previous doses administered at ≥12 months of age, and whether
         <a class="drug drug_pediatric" data-topicid="13006" href="/z/d/drug information/13006.html" rel="external">
          varicella vaccine
         </a>
         is needed  (
         <a class="graphic graphic_table graphicRef101591" href="/z/d/graphic/101591.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1787932314">
         <span class="h3">
          International travel and outbreaks
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          International travel or measles outbreak
         </strong>
         – Early administration of the first and/or second dose of MMR is recommended for [
         <a href="#rid1">
          1,50
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children traveling outside the United States. (See
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel", section on 'Measles, mumps, and rubella'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children living in or traveling to areas where there is a measles outbreak.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A measles outbreak is defined as ≥3 cases linked in time and space [
         <a href="#rid55">
          55
         </a>
         ]; the Centers for Disease Control and Prevention maintains a current list
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmeasles%2Fcases-outbreaks.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLMZ3kQGCY52l%2FpqL9bt%2FuIeT6PLWp1RiYw4fynA00m%2BYyYWj%2BbaIffqwJm7o2JPN0w%3D%3D&amp;TOPIC_ID=101273" target="_blank">
          of measles cases and outbreaks
         </a>
         in the United States [
         <a href="#rid1">
          1,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In these settings [
         <a href="#rid1">
          1,50
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children 6 through 11 months should receive one dose of MMR. Children who receive the first dose of MMR before age 12 months should receive two additional doses, separated by at least 28 days, beginning at age 12 to 15 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children ≥12 months of age should receive two doses of MMR separated by at least 28 days, with the first dose administered on or after the first birthday.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By ≥6 months of age, most infants have lost maternal antibodies and are susceptible to measles [
         <a href="#rid56">
          56,57
         </a>
         ]. Administration of the first dose of measles-containing vaccine to infants before nine months of age is safe and immunogenic, but effectiveness is lower than administration at ≥9 months of age [
         <a href="#rid37">
          37,38
         </a>
         ]. (See
         <a class="local">
          'Routine immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mumps outbreak
         </strong>
         – During a mumps outbreak:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children who are incompletely immunized against mumps should receive age-appropriate immunization  (
         <a class="graphic graphic_figure graphicRef82617" href="/z/d/graphic/82617.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'Catch-up immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children who previously received two doses of mumps-containing vaccine and are identified by public health authorities to be at increased risk of mumps (eg, due to intense exposure) should receive a third dose of mumps-containing vaccine [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8310.html" rel="external">
          "Mumps", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1787929999">
         <span class="h2">
          Other countries
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases&amp;token=orMeNG1S9%2BGAx7wBzvCzMcig%2BFKBjnete%2FGnpZrGq%2F9zhhHuQUEe2H0bnfh%2Fbg91HU5yyj2L9ghICK%2BU8ZU%2Fnm6BQ%2B9q4Zr2%2F01BK4XSa44%3D&amp;TOPIC_ID=101273" target="_blank">
          The World Health Organization
         </a>
         (WHO) recommends:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vaccination against
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases%2Fmeasles&amp;token=f%2B1rCw5Gog72y9Oc4lk7kt5MjfEh0O0u%2FsaVHPdsnP%2B7nq3iMBleX2eyghARTuvA8rMPIF1ougHZJKFwckQQH8e%2BnVCB7y45ycE0KS4MEX0%3D&amp;TOPIC_ID=101273" target="_blank">
          measles
         </a>
         for all susceptible children and adults [
         <a href="#rid59">
          59
         </a>
         ]; the first dose of measles vaccine is recommended at age 9 months for children from countries with ongoing measles transmission and at age 12 months for children from countries with low levels of measles transmission.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         WHO recommendations for postexposure prophylaxis for individuals with contraindications to measles vaccine (eg, age &lt;6 months) are similar to those in the United States. (See
         <a class="local">
          'Measles postexposure prophylaxis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vaccination against
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases%2Fmumps&amp;token=7V%2B0tm6Lc6kBPsvSlpqCfvnCt4QEzpOnphmmaWTeglGDxA0p8P6EEzZaTXkBwOdy3hBoMMAgsgnrRkL6mg7T0vJH1ytqkmH4ctTa8IoJp3w%3D&amp;TOPIC_ID=101273" target="_blank">
          mumps
         </a>
         in countries with a well-established childhood vaccination program and the capacity to maintain high levels of vaccination coverage, and where the reduction of mumps incidence is a public health priority [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Introduction of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases%2Frubella&amp;token=FJhSE8QoN1cupcuBGJncszbDBe3begpE7Q9tzJIlpAStVPQRtYY92%2BedopbW9a8W1h%2BTzW5fw7vwwPeRRY9%2FKacv0reukXk5lE%2BkTj1lTmU%3D&amp;TOPIC_ID=101273" target="_blank">
          rubella
         </a>
         -containing vaccines in countries that have not already done so if they can achieve coverage levels of ≥80 percent; rubella-containing vaccines can be introduced in conjunction with accelerated measles control and elimination activities [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Routine immunization schedules vary from country to country. Schedules for individual countries are available through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaccine-schedule.ecdc.europa.eu%2F&amp;token=hAC5nrgJRAh83rPs4U2YNoCvbRcaKCDdFzcO5xBYnRCBx4Y4AiuicnfZL3B%2BmfLV&amp;TOPIC_ID=101273" target="_blank">
          European Center for Disease Prevention and Control
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ] or the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=101273" target="_blank">
          WHO
         </a>
         [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2967078148">
         <span class="h2">
          Measles postexposure prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postexposure prophylaxis with MMR vaccine or
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         may prevent or modify the clinical course of measles in children without evidence of immunity  (
         <a class="graphic graphic_table graphicRef134368" href="/z/d/graphic/134368.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Catch-up immunization'
         </a>
         above.)
        </p>
        <p>
         In a meta-analysis of two cohort studies including 283 children [
         <a href="#rid64">
          64,65
         </a>
         ], having at least one dose of measles vaccine was 74 percent effective (95% CI 50-86 percent) in preventing measles after exposure [
         <a href="#rid2">
          2
         </a>
         ]. In observational studies, the effectiveness of measles postexposure prophylaxis ranges from 69 to 100 percent for immune
         <strong>
         </strong>
         globulin administered intramuscularly (IGIM) [
         <a href="#rid64">
          64,66-69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H984285397">
         <span class="h3">
          Indications and regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regimens for measles postexposure prophylaxis for children without evidence of measles immunity vary according to age, time of exposure, and specific contraindications to MMR vaccine (eg, severe immunodeficiency, pregnancy) [
         <a href="#rid1">
          1,50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants 0 through 5 months of age
         </strong>
         – IGIM 0.5 mL/kg (maximum dose 15 mL) within six days of exposure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants 6 through 11 months of age
         </strong>
         – Either:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MMR vaccine within 72 hours of exposure (preferred), or
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IGIM 0.5 mL/kg (maximum dose 15 mL) between four and six days of exposure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Infants age 6 through 11 months who receive MMR vaccine for postexposure prophylaxis should receive two additional doses, separated by at least 28 days, beginning at age 12 to 15 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MMR vaccination for infants who receive IGIM for prophylaxis should be deferred until six months after IGIM. (See
         <a class="local">
          'Recent receipt of blood or immune globulin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children ≥12 months of age with no doses of MMR vaccine
         </strong>
         – First dose of MMR vaccine within 72 hours of exposure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although postexposure prophylaxis is not indicated ≥72 hours after exposure, catch-up MMR immunization should be provided. (See
         <a class="local">
          'Catch-up immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children ≥12 months of age with one dose of MMR vaccine
         </strong>
         – Give second dose of MMR vaccine ≥28 days after the previous dose
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnant people who are nonimmune (measles IgG negative)
         </strong>
         – Intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) 400 mg/kg within six days of exposure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children with severely immunocompromising conditions
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Conditions
         </strong>
         –
         <strong>
         </strong>
         Severely immunocompromising conditions include [
         <a href="#rid1">
          1,70
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Severe primary immunodeficiency
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hematopoietic cell transplant until at least 12 months after completion of immunosuppressive therapy (possibly longer for those who developed graft -versus-host disease); consultation with the treating provider is suggested
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Treatment for acute lymphoblastic leukemia within and until ≥6 months of completion of immunosuppressive therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Receiving cancer chemotherapy or certain biologic immune modulators (eg, tumor necrosis factor-alpha blockers,
         <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">
          rituximab
         </a>
         ); consultation with the treating provider is suggested
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Post solid organ transplantation; consultation with the treating provider is suggested
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Receiving corticosteroid therapy equivalent to ≥2 mg/kg per day (or ≥20 mg per day of
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         for persons who weigh &gt;10 kg) for ≥14 consecutive days
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         AIDS or HIV with severe immunosuppression (ie, CD4+ T lymphocyte [CD4] percentage &lt;15 percent [all ages] or CD4 count &lt;200/microL [age &gt;5 years])
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prophylaxis regimen
         </strong>
         – The postexposure prophylaxis regimen for individuals with severely immunocompromising conditions varies with age:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         &lt;12 months of age – IGIM 0.5 mL/kg (maximum dose 15 mL) within six days of exposure
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ≥12 months –
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         400 mg/kg within six days of exposure
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Measles post exposure prophylaxis is
         <strong>
          not
         </strong>
         necessary for children who are receiving either:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Regular
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         replacement therapy at a dose of 400 mg/kg if the exposure occurred within three weeks of the last infusion, or
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Weekly subcutaneous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         if the exposure occurred after they received ≥200 mg/kg for two consecutive weeks
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3020024529">
         <span class="h3">
          Postexposure quarantine
         </span>
         <span class="headingEndMark">
          —
         </span>
         People without measles immunity or severely immunocompromised people who are exposed to measles should quarantine at home after exposure to measles (confirm that household members are immune to measles) [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         The duration of quarantine depends upon whether the exposed person received postexposure prophylaxis and the type of prophylaxis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IGIM or
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         prophylaxis – 28 days after last exposure (IGIM and IVIG prolong the incubation period)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MMR vaccine prophylaxis – First dose: 21 days after last exposure; second dose: quarantine not indicated
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No prophylaxis (eg, &gt;6 days since exposure) – 21 days after last exposure
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2435313684">
         <span class="h1">
          ADMINISTRATION
         </span>
        </p>
        <p class="headingAnchor" id="H1345357776">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to administration of
         <a class="drug drug_pediatric" data-topicid="12943" href="/z/d/drug information/12943.html" rel="external">
          measles-mumps-rubella vaccine
         </a>
         (MMR) and
         <a class="drug drug_pediatric" data-topicid="12990" href="/z/d/drug information/12990.html" rel="external">
          measles-mumps-rubella-varicella virus vaccine
         </a>
         (MMRV) include  (
         <a class="graphic graphic_table graphicRef101585" href="/z/d/graphic/101585.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid1">
          1,70
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe allergic reaction
         </strong>
         – Severe allergic reaction (eg, anaphylaxis) after a previous dose of MMR or
         <a class="drug drug_pediatric" data-topicid="13006" href="/z/d/drug information/13006.html" rel="external">
          varicella vaccine
         </a>
         (for MMRV) or to a vaccine component (eg,
         <a class="drug drug_pediatric" data-topicid="12634" href="/z/d/drug information/12634.html" rel="external">
          neomycin
         </a>
         , gelatin) is a contraindication. (See
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – Postpubertal females should be counseled to avoid becoming pregnant for 28 days after MMR because of the theoretic risk of congenital rubella syndrome [
         <a href="#rid1">
          1
         </a>
         ]. However, it is not necessary to perform a pregnancy test before administering MMR to a postpubertal female who reports that they are not pregnant and not trying to become pregnant. (See
         <a class="medical medical_review" href="/z/d/html/8312.html" rel="external">
          "Rubella in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy", section on 'Measles, mumps, rubella'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Certain immunodeficiencies
         </strong>
         – Individuals with immunodeficiency are at risk for severe complications following immunization with live attenuated virus vaccines (eg, encephalitis, pneumonitis) [
         <a href="#rid71">
          71-75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106521.html" rel="external">
          "Immunizations in patients with inborn errors of immunity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Immune deficiencies that are contraindications to MMR or MMRV include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Primary or acquired immunodeficiency (eg, cellular immunodeficiency, hypogammaglobulinemia, HIV infection with severe immune suppression)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         HIV infection with severe immunosuppression is defined as CD4+ T lymphocyte [CD4] percentage &lt;15 percent at any age or, if CD4 percentage not available, [
         <a href="#rid70">
          70,76
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CD4 count &lt;750/microL for children ≤12 months of age
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CD4 count &lt;500/microL for children 1 through 5 years of age
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CD4 count &lt;200/microL for children &gt;5 years of age
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blood dyscrasia, leukemia, lymphoma, or other malignant neoplasms affecting the bone marrow or lymphatic system.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The use of MMR in patients with cancer and in the pre- and posttransplant setting for solid organ and allogeneic hematopoietic cell transplant recipients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3899.html" rel="external">
          "Immunizations in adults with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">
          "Immunizations in solid organ transplant candidates and recipients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3882.html" rel="external">
          "Immunizations in hematopoietic cell transplant candidates and recipients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic immunosuppressive therapy, including large daily doses of corticosteroids (equivalent to ≥2 mg/kg per day or ≥20 mg per day of
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         for persons who weigh &gt;10 kg) for ≥14 consecutive days [
         <a href="#rid77">
          77
         </a>
         ]; MMR should be avoided for at least one month after high-dose corticosteroid therapy. Children receiving large daily or alternate-day corticosteroids for &lt;14 days may receive MMR immediately after discontinuation, although some experts suggest delaying MMR for two weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Lower doses of systemic corticosteroids, maintenance physiologic doses (ie, replacement therapy), and local corticosteroid injections (eg, joint, tendon) are
         <strong>
          not
         </strong>
         a contraindication to MMR [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Other examples of systemic immunosuppressive therapies that are contraindications to MMR include antitumor necrosis factor agents (eg,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="129934" href="/z/d/drug information/129934.html" rel="external">
          golimumab
         </a>
         ) [
         <a href="#rid70">
          70
         </a>
         ]. MMR should be avoided within two weeks before initiation of immunosuppression.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of congenital or hereditary immunodeficiency in parents or siblings
         <strong>
          unless
         </strong>
         the immune competence of the vaccine recipient has been substantiated clinically or verified in a laboratory.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H524758461">
         <span class="h2">
          Special circumstances
         </span>
         <span class="headingEndMark">
          —
         </span>
         Special circumstances may affect the timing of routine immunization.
        </p>
        <p class="headingAnchor" id="H1055891580">
         <span class="h3">
          Recent receipt of blood or immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The receipt of parenterally administered
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         or antibody-containing blood products can blunt or block the host response to certain live virus vaccines.
        </p>
        <p>
         For most children and adolescents, the suggested interval between receipt of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         or antibody containing blood products and administration of MMR or MMRV varies between 3 and 11 months, depending upon the product  (
         <a class="graphic graphic_table graphicRef72640" href="/z/d/graphic/72640.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid46">
          46,78,79
         </a>
         ]. MMR or MMRV vaccine can be administered before the suggested interval if the child is at high risk of measles (eg, in an outbreak setting, before international travel), but the dose is not counted as valid [
         <a href="#rid46">
          46
         </a>
         ]. The child should receive another dose after the suggested interval.
        </p>
        <p>
         Postpartum administration of MMR to females who received anti-D (Rho)
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         or blood products during the last trimester of pregnancy or at delivery is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy", section on 'Postpartum immunization'
         </a>
         .)
        </p>
        <p>
         If
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         or blood products must be given within 14 days after administration of MMR, another dose of the vaccine should be administered after the interval suggested in the table  (
         <a class="graphic graphic_table graphicRef72640" href="/z/d/graphic/72640.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H674617487">
         <span class="h3">
          Current illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether MMR/MMRV should be administered to children with current illness depends upon the severity of the illness:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate to severe illness
         </strong>
         – We suggest that MMR/MMRV be delayed in children with moderate to severe illness (eg, illnesses more severe than upper respiratory tract infection, otitis media, gastroenteritis), with or without fever, unless the vaccine is being administered for measles exposure. (See
         <a class="local">
          'Measles postexposure prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Delay of vaccination of children with moderate to severe illness avoids superimposing any adverse effects of the vaccine on the underlying illness and mistakenly attributing a manifestation of the underlying illness to the vaccine [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild illness
         </strong>
         – MMR/MMRV can be safely administered to children with mild illness, with or without fever (eg, upper respiratory infection, otitis media, diarrhea); seroconversion is not affected by mild illness [
         <a href="#rid80">
          80-82
         </a>
         ]. Failure to vaccinate children with minor illnesses results in delayed immunization and increased duration of susceptibility [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1983658965">
         <span class="h3">
          Tuberculosis testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tuberculin testing should be performed before, at the same visit as, or four to six weeks after MMR/MMRV vaccination [
         <a href="#rid1">
          1
         </a>
         ]. These vaccines may temporarily reduce
         <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">
          tuberculin skin test
         </a>
         sensitivity [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         The effect of live virus vaccination on interferon gamma release assay (IGRA) is uncertain [
         <a href="#rid1">
          1
         </a>
         ]. Pending additional information, the Advisory Committee on Immunization Practices (ACIP) suggests that IGRA testing be performed on the same day or four to six weeks after administration of MMR/MMRV.
        </p>
        <p class="headingAnchor" id="H2380969631">
         <span class="h3">
          Planned immunosuppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         If possible, MMR/MMRV should be given ≥4 weeks before planned systemic immunosuppressive therapy (eg,
         <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13077" href="/z/d/drug information/13077.html" rel="external">
          adalimumab
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="129934" href="/z/d/drug information/129934.html" rel="external">
          golimumab
         </a>
         ) [
         <a href="#rid70">
          70
         </a>
         ]. It should be avoided within two weeks before initiation of immunosuppressive therapy.
        </p>
        <p class="headingAnchor" id="H1255468484">
         <span class="h3">
          History of thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with a history of immune thrombocytopenia or nonimmune-mediated thrombocytopenia may have an increased risk of clinically significant thrombocytopenia following immunization with MMR or MMRV [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First dose
         </strong>
         – Decisions regarding administration of the first dose of MMR to children with a history of thrombocytopenia are made on a case-by-case basis contingent upon the assessment of risks and benefits. In many cases, the benefits outweigh the risks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Factors to be considered in the decision include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Among children with a history of thrombocytopenia, the magnitude of risk of recurrence with the first dose of MMR vaccine is unknown [
         <a href="#rid85">
          85-88
         </a>
         ] but likely to be small. In small series of children with a history of immune thrombocytopenia, recurrences were not observed within six weeks of receipt of MMR [
         <a href="#rid89">
          89-91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The child's likelihood of exposure to measles, mumps, and rubella (eg, plans for international travel, level of MMR vaccination coverage in the child's school and community, etc).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second dose
         </strong>
         – For children who develop thrombocytopenia after the first dose of MMR, serologic testing can be performed to determine whether the second dose of MMR is necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with protective levels of antibody to measles, mumps, and rubella do not need to receive the second dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children who lack protective levels of antibody to measles, mumps, or rubella, decisions regarding administration of the second dose of MMR are made on a case-by-case basis based upon the assessment of risks and benefits.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H166759638">
         <span class="h3">
          Antiviral medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiviral drugs active against herpes viruses (eg,
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13001" href="/z/d/drug information/13001.html" rel="external">
          valacyclovir
         </a>
         ) may interfere with response to varicella-containing vaccines. If possible, these antiviral agents should be discontinued ≥24 hours before administration of varicella-containing vaccines (eg, MMRV) and avoided for 21 days after vaccination [
         <a href="#rid92">
          92,93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3349354454">
         <span class="h3">
          Other special circumstances
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Egg allergy
         </strong>
         – Egg allergy is
         <strong>
          not
         </strong>
         a contraindication to MMR or MMRV. Children with egg allergy can safely receive MMR/MMRV without prior skin testing or special protocols [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines", section on 'Measles, mumps, and rubella'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History of measles, mumps, or rubella infection
         </strong>
         – Children who have a history of measles, mumps, or rubella infection that was diagnosed without laboratory confirmation should be vaccinated as if they have not had infection [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Routine immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children with laboratory confirmation of measles, mumps, or rubella disease are considered to be immune to that particular disease and need not be vaccinated against it. However, they generally receive two doses of MMR vaccine because monovalent vaccines for measles, mumps, and rubella are not available in the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection without severe immunosuppression
         </strong>
         – For children with HIV infection who are not severely immunocompromised and have no evidence of measles, mumps, and rubella immunity, two doses of MMR should be administered [
         <a href="#rid1">
          1,70,76
         </a>
         ]. (See
         <a class="local">
          'Catch-up immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Absence of severe immunosuppression is defined according to age as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≤5 years – CD4 percentage is ≥15 percent for at least six months; or, if CD4 percentage not available, CD4 count ≥750/microL for at least six months while ≤12 months of age or CD4 count ≥500/microL for at least six months while one through five years of age
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &gt;5 years – CD4 percentage ≥15 percent and CD4 count of ≥200/microL for at least six months if both tests are available; or, if only one test is available, CD4 percentage ≥15 percent or CD4 count of ≥200/microL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MMRV is not recommended for children with HIV infection because it has not been studied in this population [
         <a href="#rid70">
          70,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with perinatal HIV infection who received MMR before 1996 (when effective antiretroviral therapy [ART] was established) may be at risk for measles, mumps, and rubella [
         <a href="#rid94">
          94
         </a>
         ]. Such individuals who do not have evidence of immunity to measles, mumps, and rubella should receive two doses of MMR, at least 28 days apart, once effective ART has been established [
         <a href="#rid1">
          1
         </a>
         ]. Effective ART is defined by receiving ART for ≥6 months and lack of severe immunosuppression as defined above. The response to MMR is better in HIV-infected children who are receiving ART and have an undetectable viral load [
         <a href="#rid95">
          95-98
         </a>
         ]. (See
         <a class="local">
          'Catch-up immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunocompromised contact
         </strong>
         – MMR can be given to children with household contacts who are immunocompromised; the contacts are at increased risk for severe complications from natural measles infection [
         <a href="#rid70">
          70,99
         </a>
         ]. A 2007 literature review found no evidence of secondary transmission of measles, mumps, or rubella vaccine viruses from healthy vaccinees caring for or living with immunocompromised contacts [
         <a href="#rid100">
          100
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">
          "Measles: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Juvenile idiopathic arthritis
         </strong>
         – Immunization of children with juvenile idiopathic arthritis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6415.html" rel="external">
          "Oligoarticular juvenile idiopathic arthritis", section on 'Immunizations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          International adoption
         </strong>
         – Issues related to MMR immunization of children internationally adopted to the United States are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/89453.html" rel="external">
          "International adoption: Immunization considerations", section on 'Immunizations for international adoptees'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H439417133">
         <span class="h2">
          Choice between MMR and MMRV
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children age 12 months through 12 years who are due for measles, mumps, rubella, and varicella vaccines may receive either MMRV or separate MMR and varicella vaccines (administered at the same visit but at different sites). For dose 1 in children 12 through 47 months, the Centers for Disease Control and Prevention suggests that MMR and varicella vaccines be administered separately [
         <a href="#rid101">
          101
         </a>
         ]. The choice may be individualized according to caregiver preference, age, and dose  (
         <a class="graphic graphic_algorithm graphicRef134398" href="/z/d/graphic/134398.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid102">
          102
         </a>
         ]. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fvpd%2Fmmr%2Fhcp%2Fvacopt-factsheet-hcp.html&amp;token=tF%2FG0g1G66lNQera%2Bj9XUF4fWh%2FlQiyTIeZllJcizjVYAgP%2FeAMLAiLv8mGQqm8r5bb89QNMwj6%2FzrqfAttC5ZODP7s1imVWU7kg3VvM0ds%3D&amp;TOPIC_ID=101273" target="_blank">
          Centers for Disease Control and Prevention
         </a>
         provides information and a fact sheet to help caregivers understand their options.
        </p>
        <p>
         When caregivers do not have a preference, we follow the recommendations of the ACIP [
         <a href="#rid102">
          102
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First dose:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 12 through 47 months: We suggest separate MMR and varicella vaccines to MMRV; there is a slightly increased risk of febrile seizures with MMRV [
         <a href="#rid102">
          102
         </a>
         ]. MMRV is an alternative for caregivers who wish to avoid an extra injection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age 48 months through 12 years: We suggest MMRV.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Personal or family (sibling or parent) history of any type of seizures (any age): We suggest separate MMR and varicella vaccines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second dose: We suggest MMRV.
        </p>
        <p>
        </p>
        <p>
         Whether MMRV is administered for the first, second, or both the first and second dose, the immunogenicity of MMRV is similar to that of separate MMR and varicella vaccines [
         <a href="#rid103">
          103
         </a>
         ]. However, several large postlicensure studies identified an approximately twofold increased risk of febrile seizures one to two weeks after the first dose with MMRV than with separate injections of MMR and varicella, with approximately one additional febrile seizure for every 2300 to 2800 doses of MMRV [
         <a href="#rid102">
          102,104-106
         </a>
         ]. In other postlicensure studies, MMRV was not associated with increased risk of febrile seizures when administered to children age 4 to 6 years or as the second dose to toddlers [
         <a href="#rid107">
          107,108
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1372272153">
         <span class="h2">
          Dose, route, and site
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         – The dose for MMR and MMRV is 0.5 mL [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Route
         </strong>
         – All forms of MMR, including MMRV, can be administered subcutaneously with a 5/8 inch (1.6 cm), 23- to 25-gauge needle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some formulations also have been approved for intramuscular (IM) administration [
         <a href="#rid110">
          110,111
         </a>
         ]. Refer to local product information. IM injections are administered with a 22- to 25-gauge needle; the suggested needle length varies with age, sex, weight, and site of administration  (
         <a class="graphic graphic_table graphicRef60863" href="/z/d/graphic/60863.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid110">
          110,111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Immunogenicity appears to be similar with IM and subcutaneous administration [
         <a href="#rid112">
          112
         </a>
         ]. If a formulation intended for subcutaneous use is administered IM, the dose need not be repeated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Site
         </strong>
         – The site of administration varies with age and route.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Subcutaneous injections
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         &lt;12 months – Anterolateral thigh
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ≥12 months – Upper outer triceps
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IM injections
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         &lt;12 months – Anterolateral thigh
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         12 months through 2 years – Anterolateral thigh is preferred, but the deltoid muscle can be used if the muscle mass is adequate
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ≥3 years – The deltoid muscle is preferred, but the anterolateral thigh can also be used
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1043556853">
         <span class="h2">
          Administration with other vaccines
         </span>
         <span class="headingEndMark">
          —
         </span>
         MMR may be administered at the same visit as other routine childhood immunizations [
         <a href="#rid113">
          113,114
         </a>
         ]. However, if routine injectable or nasally administered live attenuated vaccines (ie, MMR, varicella, live attenuated influenza) are not administered at the same clinic visit, they should be separated by ≥28 days [
         <a href="#rid46">
          46
         </a>
         ]. Administration at &lt;28 days may impair the immune response to one of the vaccines [
         <a href="#rid115">
          115-117
         </a>
         ]. If MMR and
         <a class="drug drug_pediatric" data-topicid="13021" href="/z/d/drug information/13021.html" rel="external">
          yellow fever vaccine
         </a>
         (which is not routine) are not administered at the same clinic visit, they should be separated by ≥30 days [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3890.html" rel="external">
          "Immunizations for travel", section on 'Dosing and administration'
         </a>
         .)
        </p>
        <p>
         Live attenuated oral vaccines (eg, rotavirus vaccine, oral
         <a class="drug drug_pediatric" data-topicid="13020" href="/z/d/drug information/13020.html" rel="external">
          typhoid vaccine
         </a>
         ) can be administered at the same time as or at any interval before or after other live vaccines  (
         <a class="graphic graphic_table graphicRef112956" href="/z/d/graphic/112956.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1276242324">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse reactions to measles, mumps, and rubella combination vaccines (MMR or
         <a class="drug drug_pediatric" data-topicid="12943" href="/z/d/drug information/12943.html" rel="external">
          measles-mumps-rubella vaccine
         </a>
         [MMRV]) occur more frequently with the first than with the second dose [
         <a href="#rid119">
          119,120
         </a>
         ]. The rates of most adverse effects are similar whether the child receives MMRV or MMR and
         <a class="drug drug_pediatric" data-topicid="13006" href="/z/d/drug information/13006.html" rel="external">
          varicella vaccine
         </a>
         at the same visit [
         <a href="#rid50">
          50
         </a>
         ]. Adverse effects include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever (&gt;39.4°C) develops in 5 to 15 percent of recipients, usually within 6 to 12 days after immunization [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient rashes also occur in approximately 5 percent of recipients [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of fever and rash after MMR immunization generally is attributed to measles vaccine virus but may be due to wild-type measles or other viral illnesses [
         <a href="#rid121">
          121
         </a>
         ]; virologic studies may be warranted in children with potential exposure to wild-type measles (eg, international travel, contact with immigrants).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient lymphadenopathy occurs in 5 percent of children and 20 percent of adults [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Joint complaints (secondary to the rubella component of the vaccine) may occur 7 to 21 days after immunization [
         <a href="#rid122">
          122
         </a>
         ]. Joint pain, usually of small peripheral joints, has been reported in 0.5 percent of young children and arthralgia and transient arthritis in 25 and 10 percent of postpubertal females, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypersensitivity reactions are usually minor (wheal and flare, or urticaria) and have been attributed to trace amounts of
         <a class="drug drug_pediatric" data-topicid="12634" href="/z/d/drug information/12634.html" rel="external">
          neomycin
         </a>
         or gelatin but not to egg antigens, since MMR does not contain significant amounts of egg white cross-reacting proteins [
         <a href="#rid50">
          50,123,124
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">
          "Allergic reactions to vaccines"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although the risk of development of immune thrombocytopenia (ITP) in the six weeks after vaccination is increased [
         <a href="#rid89">
          89,125,126
         </a>
         ], vaccine-associated ITP is rare.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review of nine studies, the estimated risk of ITP after MMR vaccine (1 in 40,000 cases) was lower than the incidence of ITP after natural measles, mumps, or rubella infection (1 in 20,000 cases ) [
         <a href="#rid2">
          2
         </a>
         ] and similar to the incidence of ITP in children. In another systematic review, thrombocytopenia resolved within six months in 93 percent of cases, and severe bleeding manifestations were rare [
         <a href="#rid127">
          127
         </a>
         ]. MMR vaccination was not associated with recurrence of thrombocytopenia in children with ITP (either MMR-associated or nonvaccine-associated). (See
         <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">
          "Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MMR or MMRV is associated with an increased risk of febrile seizures within 6 to 14 days of immunization. In a systematic review of observational studies, the estimated attributable risk was one febrile seizure for every 1150 to 1700 doses of vaccine [
         <a href="#rid2">
          2
         </a>
         ]. In a meta-analysis of two large cohort studies [
         <a href="#rid128">
          128,129
         </a>
         ], the rate of febrile seizures between one and two weeks after MMR-containing immunization was 3.2 times (95% CI 2.9-3.5 times) the rate in unvaccinated children [
         <a href="#rid2">
          2
         </a>
         ]. Post-MMR febrile seizures may be associated with increased risk of recurrent febrile seizure but do not appear to be associated with increased risk of nonfebrile seizures or epilepsy [
         <a href="#rid128">
          128,129
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6183.html" rel="external">
          "Clinical features and evaluation of febrile seizures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MMR does not appear to be associated with encephalopathy or encephalitis. In a meta-analysis of two observational studies including more than one million children, no association was detected between MMR immunization and encephalopathy or encephalitis (rate ratio 0.90, 95% CI 0.50-1.61) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1276243182">
         <span class="h1">
          LACK OF ASSOCIATION WITH AUTISM SPECTRUM DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple studies have failed to demonstrate an association between measles, mumps, and rubella vaccination with autism spectrum disorder (ASD) or chronic diseases. However, there is an association between congenital rubella syndrome and ASD, highlighting a potential role for rubella immunization in the prevention of ASD [
         <a href="#rid130">
          130
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2861.html" rel="external">
          "Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1276243693">
         <span class="h1">
          RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resources related to measles, mumps, and rubella immunization in infants and children include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Advisory Committee on Immunization Practices
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Facip-recs%2Fvacc-specific%2Fmmr.html&amp;token=%2BNj5DOtb2JLO1Xa%2BQxRVJ%2BgqJ49f7pJ1Htw50nVoNeonPbmyz1ZrFZUojvwCpMf6zqU%2BQwDLkbxY%2FBCv8MjkNLPWblyNjigbXB85tr%2FA9e4%3D&amp;TOPIC_ID=101273" target="_blank">
          measles, mumps, and rubella recommendations
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fcurrent-vis.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r%2F5qdQw%2FNYQGK1y%2BHqFU7TkRZLnBxvqrSwSUrCQcXZVSA%3D%3D&amp;TOPIC_ID=101273" target="_blank">
          Vaccine information statements for measles, mumps, and rubella vaccine and measles, mumps, rubella, and varicella vaccine
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The World Health Organization position papers for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases%2Fmeasles&amp;token=f%2B1rCw5Gog72y9Oc4lk7kt5MjfEh0O0u%2FsaVHPdsnP%2B7nq3iMBleX2eyghARTuvA8rMPIF1ougHZJKFwckQQH8e%2BnVCB7y45ycE0KS4MEX0%3D&amp;TOPIC_ID=101273" target="_blank">
          measles
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases%2Fmumps&amp;token=7V%2B0tm6Lc6kBPsvSlpqCfvnCt4QEzpOnphmmaWTeglGDxA0p8P6EEzZaTXkBwOdy3hBoMMAgsgnrRkL6mg7T0vJH1ytqkmH4ctTa8IoJp3w%3D&amp;TOPIC_ID=101273" target="_blank">
          mumps
         </a>
         , and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases%2Frubella&amp;token=FJhSE8QoN1cupcuBGJncszbDBe3begpE7Q9tzJIlpAStVPQRtYY92%2BedopbW9a8W1h%2BTzW5fw7vwwPeRRY9%2FKacv0reukXk5lE%2BkTj1lTmU%3D&amp;TOPIC_ID=101273" target="_blank">
          rubella
         </a>
         [
         <a href="#rid59">
          59-61
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3464286609">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109228.html" rel="external">
          "Society guideline links: Immunizations in children and adolescents"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/111310.html" rel="external">
          "Society guideline links: Measles, mumps, and rubella vaccination"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1276243700">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83973.html" rel="external">
          "Patient education: Measles (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/82905.html" rel="external">
          "Patient education: Mumps (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/83164.html" rel="external">
          "Patient education: Rubella (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15741.html" rel="external">
          "Patient education: Vaccines for babies and children age 0 to 6 years (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15742.html" rel="external">
          "Patient education: Vaccines for children age 7 to 18 years (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1214.html" rel="external">
          "Patient education: Why does my child need vaccines? (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1216.html" rel="external">
          "Patient education: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1218.html" rel="external">
          "Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1276243707">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Measles, mumps, and rubella disease
         </strong>
         – Measles, mumps, and rubella infections may have serious complications (eg, encephalitis, orchitis and oophoritis, congenital rubella syndrome). (See
         <a class="local">
          'Measles, mumps, and rubella disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccine effectiveness
         </strong>
         – Introduction of routine measles, mumps, and rubella immunization in the United States reduced the numbers of cases of measles, mumps, and rubella infections  (
         <a class="graphic graphic_figure graphicRef101586 graphicRef101590 graphicRef70446" href="/z/d/graphic/101586.html" rel="external">
          figure 1A-C
         </a>
         ). Measles vaccine is &gt;95 percent effective, and mumps vaccine is &gt;85 percent effective after two doses; rubella vaccine is approximately 90 percent effective after one dose. (See
         <a class="local">
          'Vaccine effectiveness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and schedules in the United States
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Routine immunization – For susceptible children ≥12 months, we recommend routine measles, mumps, and rubella vaccination (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). These diseases may have serious complications, and the vaccines are safe and effective.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The routine schedule
         <a class="drug drug_pediatric" data-topicid="12943" href="/z/d/drug information/12943.html" rel="external">
          measles-mumps-rubella vaccine
         </a>
         (MMR) or
         <a class="drug drug_pediatric" data-topicid="12990" href="/z/d/drug information/12990.html" rel="external">
          measles-mumps-rubella-varicella virus vaccine
         </a>
         (MMRV) consists of two doses: the first at age 12 through 15 months and the second at age 4 through 6 years. (See
         <a class="local">
          'Routine immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Catch-up immunization – Catch-up MMR immunization  (
         <a class="graphic graphic_table graphicRef101591" href="/z/d/graphic/101591.html" rel="external">
          table 3
         </a>
         ) is necessary for children whose immunization status is unknown or who lack appropriate evidence of immunity  (
         <a class="graphic graphic_table graphicRef134368" href="/z/d/graphic/134368.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Catch-up immunization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other indications – Other indications for routine or early MMR immunization include international travel, outbreaks, and measles postexposure prophylaxis. (See
         <a class="local">
          'International travel and outbreaks'
         </a>
         above and
         <a class="local">
          'Measles postexposure prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and schedules in other countries
         </strong>
         – MMR immunization schedules for other countries are available through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaccine-schedule.ecdc.europa.eu%2F&amp;token=hAC5nrgJRAh83rPs4U2YNoCvbRcaKCDdFzcO5xBYnRCBx4Y4AiuicnfZL3B%2BmfLV&amp;TOPIC_ID=101273" target="_blank">
          European Center for Disease Prevention and Control
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ] or the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=101273" target="_blank">
          World Health Organization
         </a>
         [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="local">
          'Other countries'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Contraindications – The table summarizes contraindications to MMR and MMRV  (
         <a class="graphic graphic_table graphicRef101585" href="/z/d/graphic/101585.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Special circumstances – The table summarizes circumstances that may affect the timing of routine immunization  (
         <a class="graphic graphic_table graphicRef134369" href="/z/d/graphic/134369.html" rel="external">
          table 8
         </a>
         ). (See
         <a class="local">
          'Special circumstances'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Choice between MMR and MMRV  (
         <a class="graphic graphic_algorithm graphicRef134398" href="/z/d/graphic/134398.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         When administering the first dose to a child &lt;48 months old or any dose of vaccine to a child who has a personal or family history of seizures, we suggest separate MMR and varicella vaccines (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). MMRV is a reasonable alternative for children without a personal/family history of seizures if the caregivers wish to avoid an extra injection.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         When administering the vaccine to a child ≥48 months old, we suggest MMRV (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Choice between MMR and MMRV'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Route and dose – All forms of MMR, including MMRV, can be administered subcutaneously. Some formulations are also approved for intramuscular administration. Refer to local product information. MMR and MMRV are usually administered in the upper outer triceps for children ≥12 months of age and the lateral thigh for infants &lt;12 months of age. The dose is 0.5 mL. (See
         <a class="local">
          'Administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse effects of MMR and MMRV are more common with the first than the second dose. They include fever, rash, lymphadenopathy, joint complaints, hypersensitivity reactions, immune thrombocytopenia, and seizures. (See
         <a class="local">
          'Adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple studies have failed to demonstrate an association between MMR and autism spectrum disorder (ASD) or other chronic diseases. (See
         <a class="medical medical_review" href="/z/d/html/2861.html" rel="external">
          "Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Pietrantonj C, Rivetti A, Marchione P, et al. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev 2021; 11:CD004407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel MK, Goodson JL, Alexander JP Jr, et al. Progress Toward Regional Measles Elimination - Worldwide, 2000-2019. MMWR Morb Mortal Wkly Rep 2020; 69:1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minta AA, Ferrari M, Antoni S, et al. Progress Toward Measles Elimination - Worldwide, 2000-2022. MMWR Morb Mortal Wkly Rep 2023; 72:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gahr P, DeVries AS, Wallace G, et al. An outbreak of measles in an undervaccinated community. Pediatrics 2014; 134:e220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherry JD, Zahn M. Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California. Clin Infect Dis 2018; 67:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopkins Tanne J. Measles: two US outbreaks are blamed on low vaccination rates. BMJ 2019; 364:l312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisker AB, Rodrigues A, Martins C, et al. Reduced All-cause Child Mortality After General Measles Vaccination Campaign in Rural Guinea-Bissau. Pediatr Infect Dis J 2015; 34:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mogensen SW, Aaby P, Smedman L, et al. Introduction of standard measles vaccination in an urban African community in 1979 and overall child survival: a reanalysis of data from a cohort study. BMJ Open 2016; 6:e011317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sørup S, Benn CS, Poulsen A, et al. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA 2014; 311:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins JP, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 2016; 355:i5170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mina MJ, Metcalf CJ, de Swart RL, et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 2015; 348:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries RD, de Swart RL. Measles immune suppression: functional impairment or numbers game? PLoS Pathog 2014; 10:e1004482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 2019; 366:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrova VN, Sawatsky B, Han AX, et al. Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Sci Immunol 2019; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behrens L, Cherry JD, Heininger U, Swiss Measles Immune Amnesia Study Group. The Susceptibility to Other Infectious Diseases Following Measles During a Three Year Observation Period in Switzerland. Pediatr Infect Dis J 2020; 39:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang L, Grenfell BT, Mina MJ. Waning immunity and re-emergence of measles and mumps in the vaccine era. Curr Opin Virol 2020; 40:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepersky L, Marin M, Zhang J, et al. Mumps in Vaccinated Children and Adolescents: 2007-2019. Pediatrics 2021; 148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome--United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279.
          </a>
         </li>
         <li class="breakAll">
          Pan American Health Organization. Americas region is declared the world's first to eliminate rubella. Available at: www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=10798&amp;Itemid=1926&amp;lang=en (Accessed on May 01, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Three cases of congenital rubella syndrome in the postelimination era--Maryland, Alabama, and Illinois, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Brief report: Imported case of congenital rubella syndrome--New Hampshire, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1160.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. WHO recommendations for routine immunization - summary tables. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---summary-tables (Accessed on October 05, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krow-Lucal E, Marin M, Shepersky L, et al. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redd SC, King GE, Heath JL, et al. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis 2004; 189 Suppl 1:S116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carazo Perez S, De Serres G, Bureau A, Skowronski DM. Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose. Clin Infect Dis 2017; 65:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007; 161:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidkin I, Jokinen S, Broman M, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008; 197:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz LE, Albrecht P, Orenstein WA, et al. Persistence of measles antibody after revaccination. J Infect Dis 1992; 166:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward BJ, Boulianne N, Ratnam S, et al. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995; 172:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBaron CW, Forghani B, Matter L, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 200:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillary IB, Griffith AH. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 1984; 2:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christenson B, Böttiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994; 12:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBaron CW, Forghani B, Beck C, et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009; 199:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gothefors L, Bergström E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis 2001; 33:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broliden K, Abreu ER, Arneborn M, Böttiger M. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme. Vaccine 1998; 16:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nic Lochlainn LM, de Gier B, van der Maas N, et al. Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nic Lochlainn LM, de Gier B, van der Maas N, et al. Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinkman ID, Butler AL, de Wit J, et al. Measles Vaccination Elicits a Polyfunctional Antibody Response, Which Decays More Rapidly in Early Vaccinated Children. J Infect Dis 2022; 225:1755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers DV, Gindler JS, Atkinson WL, Markowitz LE. High attack rates and case fatality during a measles outbreak in groups with religious exemption to vaccination. Pediatr Infect Dis J 1993; 12:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Measles outbreak--New York City, 1990-1991. MMWR Morb Mortal Wkly Rep 1991; 40:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Measles outbreak--Washington, 1989: failure of delayed postexposure prophylaxis with vaccine. MMWR Morb Mortal Wkly Rep 1990; 39:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Update: measles outbreak--Chicago, 1989. MMWR Morb Mortal Wkly Rep 1990; 39:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowhani-Rahbar A, Fireman B, Lewis E, et al. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr 2013; 167:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hambidge SJ, Newcomer SR, Narwaney KJ, et al. Timely versus delayed early childhood vaccination and seizures. Pediatrics 2014; 133:e1492.
          </a>
         </li>
         <li class="breakAll">
          Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Timing and Spacing of Immunobiologics. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (Accessed on October 06, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson JC, Pearson JA, Markowitz LE, et al. An evaluation of measles revaccination among school-entry-aged children. Pediatrics 1996; 97:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poland GA, Jacobson RM, Thampy AM, et al. Measles reimmunization in children seronegative after initial immunization. JAMA 1997; 277:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis RL, Marcuse E, Black S, et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997; 100:767.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Measles. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics 2021. p.503.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogbuanu IU, Kutty PK, Hudson JM, et al. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics 2012; 130:e1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson GE, Aguon A, Valencia E, et al. Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010. Pediatr Infect Dis J 2013; 32:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Date AA, Kyaw MH, Rue AM, et al. Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population. J Infect Dis 2008; 197:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin M, Fiebelkorn AP, Bi D, et al. Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine. Clin Infect Dis 2021; 73:e1546.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases. Measles. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.html (Accessed on October 06, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Science M, Savage R, Severini A, et al. Measles Antibody Levels in Young Infants. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leuridan E, Hens N, Hutse V, et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010; 340:c1626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep 2018; 67:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Measles vaccines: WHO position paper – April 2017. Wkly Epidemiol Rec 2017; 92:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mumps virus vaccines. Wkly Epidemiol Rec 2007; 82:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubella vaccines: WHO position paper -- July 2020. Wkly Epidemiol Rec 2020; 95:301.
          </a>
         </li>
         <li class="breakAll">
          European Centre for Disease Prevention and Control. Vaccine schedules in all countries of the European Union. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx (Accessed on October 13, 2021).
         </li>
         <li class="breakAll">
          World Health Organization. WHO vaccine-preventable diseases: monitoring system. https://apps.who.int/immunization_monitoring/globalsummary (Accessed on October 13, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013. Clin Infect Dis 2017; 65:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrabeig I, Rovira A, Rius C, et al. Effectiveness of measles vaccination for control of exposed children. Pediatr Infect Dis J 2011; 30:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lejeune A, Martin L, Santibanez S, et al. Postexposure prophylaxis with intravenous immunoglobulin G prevents infants from getting measles. Acta Paediatr 2017; 106:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheppeard V, Forssman B, Ferson MJ, et al. The effectiveness of prophylaxis for measles contacts in NSW. N S W Public Health Bull 2009; 20:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young MK, Nimmo GR, Cripps AW, Jones MA. Post-exposure passive immunisation for preventing measles. Cochrane Database Syst Rev 2014; :CD010056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bigham M, Murti M, Fung C, et al. Estimated protective effectiveness of intramuscular immune serum globulin post-exposure prophylaxis during a measles outbreak in British Columbia, Canada, 2014. Vaccine 2017; 35:2723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon TP, Tchertkoff V, Win H. Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy. A case report. Acta Cytol 1998; 42:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. Clin Infect Dis 1999; 29:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baram TZ, Gonzalez-Gomez I, Xie ZD, et al. Subacute sclerosing panencephalitis in an infant: diagnostic role of viral genome analysis. Ann Neurol 1994; 36:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep 1996; 45:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derryck A, LaRussa P, Steinberg S, et al. Varicella and zoster in children with human immunodeficiency virus infection. Pediatr Infect Dis J 1998; 17:931.
          </a>
         </li>
         <li class="breakAll">
          Department of Health and Human Services. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Available at: aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf (Accessed on May 02, 2019).
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Immunization and other considerations in immunocompromised children. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.72.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siber GR, Werner BG, Halsey NA, et al. Interference of immune globulin with measles and rubella immunization. J Pediatr 1993; 122:204.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Active immunization after receipt of immune globulin or other blood products. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.40.
         </li>
         <li>
          <a class="nounderline abstract_t">
           King GE, Markowitz LE, Heath J, et al. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. JAMA 1996; 275:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994; 94:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratnam S, West R, Gadag V. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. J Pediatr 1995; 127:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farizo KM, Stehr-Green PA, Markowitz LE, Patriarca PA. Vaccination levels and missed opportunities for measles vaccination: a record audit in a public pediatric clinic. Pediatrics 1992; 89:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brickman HF, Beaudry PH, Marks MI. The timing of tuberculin tests in relation to immunization with live viral vaccines. Pediatrics 1975; 55:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieminen U, Peltola H, Syrjälä MT, et al. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993; 82:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996; 15:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drachtman RA, Murphy S, Ettinger LJ. Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 1994; 148:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 1996; 97:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008; 121:e687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stowe J, Kafatos G, Andrews N, Miller E. Idiopathic thrombocytopenic purpura and the second dose of MMR. Arch Dis Child 2008; 93:182.
          </a>
         </li>
         <li class="breakAll">
          Kroger  A, Bahta L, Hunter P, et al. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Contraindications and Precautions. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html (Accessed on January 05, 2022).
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Varicella-zoster virus infections. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DB, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics 2021. p.831.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siberry GK, Patel K, Bellini WJ, et al. Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. Clin Infect Dis 2015; 61:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkelhamer S, Borock E, Elsen C, et al. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin Infect Dis 2001; 32:1090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007; 45:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowson K, Tan A, Donaghy S, et al. Measles reimmunization may not be effective in protecting HIV-infected children. Pediatr Infect Dis J 2015; 34:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehtani NJ, Rosman L, Moss WJ. Immunogenicity and Safety of the Measles Vaccine in HIV-Infected Children: An Updated Systematic Review. Am J Epidemiol 2019; 188:2240.
          </a>
         </li>
         <li class="breakAll">
          Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Altered Immunocompetence. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html (Accessed on January 05, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamboj M, Sepkowitz KA. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp Epidemiol 2007; 28:702.
          </a>
         </li>
         <li class="breakAll">
          Recommended child and adolescent immunization schedule for ages 18 years and younger, United States 2024. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf (Accessed on January 01, 2024).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin M, Broder KR, Temte JL, et al. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.
          </a>
         </li>
         <li class="breakAll">
          ProQuad measles, mumps, rubella, and varicella virus vaccine for subcutaneous injection. US Food &amp; Drug (FDA) approved product information. Revised March 2014. US National Library of Medicine. Available at: www.dailymed.nlm.nih.gov (Accessed on May 06, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009; 27:4656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacDonald SE, Dover DC, Simmonds KA, Svenson LW. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ 2014; 186:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein NP, Lewis E, Baxter R, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics 2012; 129:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macartney K, Gidding HF, Trinh L, et al. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia. JAMA Pediatr 2017; 171:992.
          </a>
         </li>
         <li class="breakAll">
          Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Vaccine Administration. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html (Accessed on January 05, 2022).
         </li>
         <li class="breakAll">
          M-M-R II (measles, mumps, and rubella virus vaccine live). US Food and Drug Administration approved product information. Revised February, 2023. Available online at: https://www.fda.gov/media/75191/download (Accessed on March 01, 2023).
         </li>
         <li class="breakAll">
          ProQuad measles, mumps, rubella, and varicella virus vaccine. US Food and Drug Administration approved product information. Revised February, 2023. Available online at: https://www.fda.gov/media/147562/download (Accessed on March 01, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knuf M, Zepp F, Meyer CU, et al. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. Eur J Pediatr 2010; 169:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassidy WM, Jones G, Williams K, et al. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health 2005; 36:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016; 35:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PETRALLI JK, MERIGAN TC, WILBUR JR. ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN. Lancet 1965; 2:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PETRALLI JK, MERIGAN TC, WILBUR JR. CIRCULATING INTERFERON AFTER MEASLES VACCINATION. N Engl J Med 1965; 273:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics 2003; 112:e98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBaron CW, Bi D, Sullivan BJ, et al. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics 2006; 118:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuter BJ, Brown M, Wiedmann RT, et al. Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009. Pediatr Infect Dis J 2016; 35:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ting CY, Tee NW, Thoon KC. Could a fever and rash after the measles, mumps and rubella vaccination indicate wild-type measles? Acta Paediatr 2015; 104:e232.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Rubella. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.648.
         </li>
         <li>
          <a class="nounderline abstract_t">
           James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995; 332:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck SA, Williams LW, Shirrell MA, Burks AW. Egg hypersensitivity and measles-mumps-rubella vaccine administration. Pediatrics 1991; 88:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics 2012; 129:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein NP, Lewis E, Fireman B, et al. Safety of measles-containing vaccines in 1-year-old children. Pediatrics 2015; 135:e321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010; 156:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chess S, Fernandez P, Korn S. Behavioral consequences of congenital rubella. J Pediatr 1978; 93:699.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 101273 Version 53.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23760231" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34806766" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Vaccines for measles, mumps, rubella, and varicella in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33180759" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Progress Toward Regional Measles Elimination - Worldwide, 2000-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37971951" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Progress Toward Measles Elimination - Worldwide, 2000-2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24913790" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : An outbreak of measles in an undervaccinated community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29878209" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30665901" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Measles: two US outbreaks are blamed on low vaccination rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26379164" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Reduced All-cause Child Mortality After General Measles Vaccination Campaign in Rural Guinea-Bissau.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27998896" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Introduction of standard measles vaccination in an urban African community in 1979 and overall child survival: a reanalysis of data from a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24570246" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27737834" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25954009" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25522010" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Measles immune suppression: functional impairment or numbers game?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31672891" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31672862" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32084116" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Susceptibility to Other Infectious Diseases Following Measles During a Three Year Observation Period in Switzerland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32634672" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Waning immunity and re-emergence of measles and mumps in the vaccine era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34814181" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mumps in Vaccinated Children and Adolescents: 2007-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15788995" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Elimination of rubella and congenital rubella syndrome--United States, 1969-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15788995" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Elimination of rubella and congenital rubella syndrome--United States, 1969-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23535689" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Three cases of congenital rubella syndrome in the postelimination era--Maryland, Alabama, and Illinois, 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16323362" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Brief report: Imported case of congenital rubella syndrome--New Hampshire, 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16323362" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Brief report: Imported case of congenital rubella syndrome--New Hampshire, 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36395065" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15106100" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28595358" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17339511" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18419470" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1607699" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Persistence of measles antibody after revaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7594723" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19659440" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6531967" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8303939" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19113988" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11515768" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9607050" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31548081" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31548079" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34134138" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Measles Vaccination Elicits a Polyfunctional Antibody Response, Which Decays More Rapidly in Early Vaccinated Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8483622" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : High attack rates and case fatality during a measles outbreak in groups with religious exemption to vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1902282" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Measles outbreak--New York City, 1990-1991.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2118587" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Measles outbreak--Washington, 1989: failure of delayed postexposure prophylaxis with vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2110291" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Update: measles outbreak--Chicago, 1989.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24126936" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24843064" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Timely versus delayed early childhood vaccination and seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24843064" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Timely versus delayed early childhood vaccination and seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8628596" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : An evaluation of measles revaccination among school-entry-aged children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9087472" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Measles reimmunization in children seronegative after initial immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9346975" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9346975" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23129075" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23099425" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18419346" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32766827" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32766827" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31753911" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Measles Antibody Levels in Young Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20483946" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Early waning of maternal measles antibodies in era of measles elimination: longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29324728" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28459148" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Measles vaccines: WHO position paper–April 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17304707" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mumps virus vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rubella vaccines: WHO position paper -- July 2020
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Rubella vaccines: WHO position paper -- July 2020
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Rubella vaccines: WHO position paper -- July 2020
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29028959" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20844460" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effectiveness of measles vaccination for control of exposed children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27748542" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Postexposure prophylaxis with intravenous immunoglobulin G prevents infants from getting measles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19552854" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The effectiveness of prophylaxis for measles contacts in NSW.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24687262" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Post-exposure passive immunisation for preventing measles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28392140" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Estimated protective effectiveness of intramuscular immune serum globulin post-exposure prophylaxis during a measles outbreak in British Columbia, Canada, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9622696" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Subacute measles encephalitis with AIDS diagnosed by fine needle aspiration biopsy. A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10589903" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Measles inclusion-body encephalitis caused by the vaccine strain of measles virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8024248" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Subacute sclerosing panencephalitis in an infant: diagnostic role of viral genome analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8676852" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802645" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Varicella and zoster in children with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802645" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Varicella and zoster in children with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802645" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Varicella and zoster in children with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8429432" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Interference of immune globulin with measles and rubella immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8429432" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Interference of immune globulin with measles and rubella immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8594268" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7936862" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7658276" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1557235" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Vaccination levels and missed opportunities for measles vaccination: a record audit in a public pediatric clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1143978" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The timing of tuberculin tests in relation to immunization with live viral vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8495082" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8684885" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8130872" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Exacerbation of chronic idiopathic thrombocytopenic purpura following measles-mumps-rubella immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8628619" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18310189" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207170" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Idiopathic thrombocytopenic purpura and MMR vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17962371" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Idiopathic thrombocytopenic purpura and the second dose of MMR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17962371" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Idiopathic thrombocytopenic purpura and the second dose of MMR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17962371" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Idiopathic thrombocytopenic purpura and the second dose of MMR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26060291" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11264038" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17683001" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25876100" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Measles reimmunization may not be effective in protecting HIV-infected children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31210268" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Immunogenicity and Safety of the Measles Vaccine in HIV-Infected Children: An Updated Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31210268" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Immunogenicity and Safety of the Measles Vaccine in HIV-Infected Children: An Updated Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520544" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520544" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20448530" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20448530" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19520201" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20587679" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24914115" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22473362" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Measles-containing vaccines and febrile seizures in children age 4 to 6 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28806450" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28806450" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28806450" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28806450" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20148263" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15737773" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26398743" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14346758" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : ACTION OF ENDOGENOUS INTERFERON AGAINST VACCINIA INFECTION IN CHILDREN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14306336" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : CIRCULATING INTERFERON AFTER MEASLES VACCINATION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12897314" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20671663" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015532" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27254037" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25646657" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Could a fever and rash after the measles, mumps and rubella vaccination indicate wild-type measles?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25646657" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Could a fever and rash after the measles, mumps and rubella vaccination indicate wild-type measles?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7708070" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Safe administration of the measles vaccine to children allergic to eggs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1945631" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Egg hypersensitivity and measles-mumps-rubella vaccine administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22232308" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : The risk of immune thrombocytopenic purpura after vaccination in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25560438" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Safety of measles-containing vaccines in 1-year-old children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20097358" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11547719" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15265850" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/702254" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Behavioral consequences of congenital rubella.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
